Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

cardiovascular · Mechanism Report

Does LDL particle number predict cardiovascular risk even when LDL cholesterol is normal?

LDL particle number (LDL-P) predicts cardiovascular risk more precisely than LDL-C and remains a meaningful risk marker when LDL-C is within the normal range.

SupportedJune 19, 202614 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

LDL particle number reflects the number of atherogenic lipoprotein particles and predicts cardiovascular risk even when LDL cholesterol is in the normal range.

laying out figure…
All 5 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim states that LDL-P directly quantifies the count of atherogenic particles and can identify elevated risk even if LDL-C is normal. The mechanism links higher particle counts (and correlated ApoB levels) to greater arterial retention and plaque formation—especially via small, dense LDL—explaining why particle number better reflects total atherogenic burden.

Verified conclusion

Low-density lipoprotein particle number (LDL-P) provides a more precise quantification of atherogenic risk than traditional LDL cholesterol (LDL-C) measurements, particularly in individuals where these two markers are discordant.

Clinical effectiveness and risk prediction

Evidence consistently demonstrates that LDL-P is an independent and often superior predictor of cardiovascular risk. While LDL-C measures the total mass of cholesterol within particles, LDL-P counts the particles themselves. In cases of discordance—where LDL-C is "normal" or low but LDL-P remains high—individuals face a significantly elevated risk for major adverse cardiovascular events (MACE).

  • Research indicates that relying solely on LDL-C can misclassify cardiovascular risk in 20% to 50% of patients.
  • Clinical studies show that patients with high concentrations of Apolipoprotein B (ApoB)—the protein marker found on every LDL particle—have significantly higher hazard ratios for cardiovascular events, even when their LDL-C levels appear well-controlled.
  • In younger populations, individuals with elevated particle counts were nearly 2.5 times more likely to develop large-artery atherosclerosis despite having low traditional LDL-C levels.

Mechanistic explanations

The superiority of LDL-P as a risk marker is rooted in the biological process of plaque formation.

  • Particle Retention: Cardiovascular risk is primarily driven by the number of particles that penetrate the endothelial lining and become trapped in the arterial wall. Because each LDL particle contains exactly one ApoB molecule, LDL-P (and its surrogate ApoB) directly reflects the total concentration of these atherogenic vehicles.
  • Size and Density: High particle numbers often signal an abundance of small, dense LDL (sdLDL) subfractions. These smaller particles are more potent because they more easily penetrate the arterial wall and have a higher affinity for arterial proteoglycans, leading to faster oxidation and inflammatory plaque development.
  • Total Burden: The total atherogenic burden is a function of the particle count rather than the volume of cholesterol those particles carry. This explains why a patient can have a low "cholesterol" reading but a high "particle" count, maintaining a high risk for arterial damage.

Bottom line

LDL particle number is a scientifically validated measure of the total atherogenic burden. It remains a critical predictor of cardiovascular risk even when traditional LDL cholesterol is within a normal range, as it directly reflects the concentration of particles capable of initiating and driving arterial disease.

References

  1. Particle Number vs. Cholesterol Mass: The Emerging Role of ApoB in Refining Cardiovascular Risk Stratification — sciltp.com ↗
  2. Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk — pmc.ncbi.nlm.nih.gov ↗
  3. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. — linkinghub.elsevier.com ↗
  4. NMR Insights into Lipoprotein Particles: analyzing correlations with traditional lipid measurements — academic.oup.com ↗
  5. Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention — academic.oup.com ↗
  6. Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events — pmc.ncbi.nlm.nih.gov ↗
  7. Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter? — pmc.ncbi.nlm.nih.gov ↗
  8. Discordance between LDL-C and apolipoprotein B is associated with large-artery-atherosclerosis ischemic stroke in patients ⩽70 years of age — academic.oup.com ↗
  9. Comparison of Current International Guidelines for the Management of Dyslipidemia — mdpi.com ↗
  10. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. — pmc.ncbi.nlm.nih.gov ↗
  11. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL — mdpi.com ↗
  12. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases — downloads.hindawi.com ↗
  13. Sex differences in the correlation between lipids related to cardiovascular risk factors and small dense LDL particles in patients with type 2 diabetes — aem-sbem.com ↗
  14. The effect of intakes of fish and Camelina sativa oil on atherogenic and anti-atherogenic functions of LDL and HDL particles: A randomized controlled trial. — linkinghub.elsevier.com ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible10 sourcesAre F2-isoprostanes biomarkers of lipid peroxidation and does oxidized LDL contribute to atherosclerosis?→Plausible10 sourcesDo hs-CRP, Lp-PLA2, and myeloperoxidase reflect different cardiovascular risk signals?→